Pegylated erythropoietin - PharmaEssentia

Drug Profile

Pegylated erythropoietin - PharmaEssentia

Alternative Names: PEG-EPO - PharmaEssentia

Latest Information Update: 13 Oct 2015

Price : $50

At a glance

  • Originator PharmaEssentia Corporation
  • Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Anaemia

Most Recent Events

  • 31 Dec 2014 Preclinical trials in Anaemia in Taiwan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top